Literature DB >> 10220565

Novel actions of inverse agonists on 5-HT2C receptor systems.

K A Berg1, B D Stout, J D Cropper, S Maayani, W P Clarke.   

Abstract

In cell systems where ligand-independent receptor activity is optimized (such as when receptors are overexpressed or mutated), acute treatment with inverse agonists reduces basal effector activity whereas prolonged exposure leads to sensitization of receptor systems and receptor up-regulation. Few studies, however, have reported effects of inverse agonists in systems where nonmutated receptors are expressed at relatively low density. Here, we investigated the effects of inverse agonists at human serotonin (5-HT)2C receptors expressed stably in Chinese hamster ovary cells ( approximately 250 fmol/mg protein). In these cells, there is no receptor reserve for 5-HT and 5-HT2C inverse agonists did not reduce basal inositol phosphate (IP) accumulation nor arachidonic acid (AA) release but behaved as simple competitive antagonists, suggesting that these receptors are not overexpressed. Prolonged treatment (24 h) with inverse agonists enhanced selectively 5-HT2C-mediated IP accumulation but not AA release. The enhancing effect occurred within 4 h of treatment, reversed within 3 to 4 h (after 24-h treatment), and could be blocked with neutral antagonists or weak positive agonists. The enhanced responsiveness was not due to receptor up-regulation but may involve changes in the expression of the G protein, Galphaq/11 and possibly Galpha12 and Galpha13. Interestingly, 24-h exposure to inverse agonists acting at 5-HT2C receptors also selectively enhanced IP accumulation, but not AA release, elicited by activation of endogenous purinergic receptors. These data suggest that actions of inverse agonists may be mediated through effects on receptor systems that are not direct targets for these drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10220565

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  24 in total

Review 1.  Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.

Authors:  R A de Ligt; A P Kourounakis; A P IJzerman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  In vivo pharmacological resultant analysis reveals noncompetitive interactions between opioid antagonists in the rat tail-withdrawal assay.

Authors:  E A Walker
Journal:  Br J Pharmacol       Date:  2006-10-30       Impact factor: 8.739

Review 3.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

4.  Effect of serotonin depletion on 5-HT2A-mediated learning in the rabbit: evidence for constitutive activity of the 5-HT2A receptor in vivo.

Authors:  A G Romano; J L Quinn; R Liu; K D Dave; D Schwab; G Alexander; V J Aloyo; J A Harvey
Journal:  Psychopharmacology (Berl)       Date:  2005-12-21       Impact factor: 4.530

5.  Treatment with inverse agonists enhances baseline atrial contractility in transgenic mice with chronic beta2-adrenoceptor activation.

Authors:  S Nagaraja; S Iyer; X Liu; J Eichberg; R A Bond
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

6.  Atypical antipsychotics and inverse agonism at 5-HT2 receptors.

Authors:  Laura C Sullivan; William P Clarke; Kelly A Berg
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

7.  Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex.

Authors:  C Nocjar; K D Alex; A Sonneborn; A I Abbas; B L Roth; E A Pehek
Journal:  Neuroscience       Date:  2015-03-27       Impact factor: 3.590

8.  h5-HT(1B) receptor-mediated constitutive Galphai3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT.

Authors:  Adrian Newman-Tancredi; Didier Cussac; Laetitia Marini; Manuelle Touzard; Mark J Millan
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

9.  Constitutive Desensitization of Opioid Receptors in Peripheral Sensory Neurons.

Authors:  Laura C Sullivan; Teresa S Chavera; Raehannah J Jamshidi; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2016-09-22       Impact factor: 4.030

10.  Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat.

Authors:  Alice Egerton; Rabia Ahmad; Ella Hirani; Paul M Grasby
Journal:  Psychopharmacology (Berl)       Date:  2008-07-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.